Three weeks after taking over as CEO of Lexicon Pharmaceuticals back in 2024, Michael Exton suggested the company close its commercial operations. He knew the Texas-based biopharma needed to change ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Before the Speedmaster went to the moon, before the Seamaster found its way onto James Bond’s wrist, there was the Constellation. First arriving in 1952, the Constellation was Omega’s first modern ...

Novo Nordisk began a Phase 1 study of an oral obesity-drug candidate it agreed to license from Lexicon Pharmaceuticals last year. The study is investigating the safety and tolerability of the drug, ...

Designing effective lexicons is a critical component of any communications surveillance program, yet even mature teams encounter avoidable pitfalls that diminish accuracy, create operational strain, ...

How can compliance teams build lexicon policies that keep pace with shifting communication risks and regulatory scrutiny? This article explains what lexicons are, why they matter, and how to design ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Lexicon Inc., a Little Rock-based construction management and steel fabrication company, said Thursday it has become a private, employee-owned company. Lexicon said the decision comes after a ...

The company also stands to gain from recent regulatory FDA guidance aimed at streamlining the development of non-opioid painkillers, Jefferies analysts suggested. Following a successful end-of-Phase ...

Lexicon Pharmaceuticals is positioned for a potential turnaround with three key drug programs and recent partnerships, despite a challenging history. LXRX's sotagliflozin faces uncertain FDA approval ...

THE WOODLANDS, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2025, and provided an ...